United States Patent 7,056,712: Claims, Tadalafil Patent Landscape, and Generic Entry Risk

United States Patent 7,056,712, titled "Tadalafil for the Treatment of Erectile Dysfunction," was assigned to Eli Lilly and Company and covered dosing methods for tadalafil, the active ingredient in Cialis. The patent was one of several Lilly patents supporting Cialis exclusivity. Its claims focused on administering tadalafil for erectile dysfunction rather than broadly claiming the tadalafil molecule itself.

The patent has reached the end of its ordinary U.S. patent term. It no longer presents a material standalone barrier to FDA-approved generic tadalafil entry, although related formulation, method-of-use, regulatory-exclusivity, and manufacturing issues remain relevant to commercial strategy.

What does U.S. Patent 7,056,712 cover?

US7056712 covers methods for treating erectile dysfunction by administering tadalafil to a patient in a therapeutically effective amount. The patent is a use patent, not the principal composition-of-matter patent for tadalafil.

Field	Information
Patent	U.S. Patent 7,056,712
Title	Tadalafil for the Treatment of Erectile Dysfunction
Patent holder	Eli Lilly and Company
Active ingredient	Tadalafil
Therapeutic area	Erectile dysfunction
Dosage form	Oral pharmaceutical dosage forms
Patent type	Method of treatment
Original filing period	Early 2000s
Grant date	June 6, 2006
Approximate ordinary expiration	2021
FDA relevance	Historically listed for Cialis and related tadalafil products
Current practical status	Expired as a blocking patent

The protected subject matter centered on the clinical use of tadalafil for erectile dysfunction, including administration of a therapeutically effective dose. The patent did not give Lilly perpetual control over every tadalafil product. A competitor could avoid infringement by challenging claim scope, using a non-infringing indication, relying on an expired patent, or entering after expiration.

What are the key claims of US7056712?

The claims should be analyzed as a method-of-use group with several limitations:

The presence of a patient suffering from erectile dysfunction.
Administration of tadalafil to that patient.
Use of a therapeutically effective amount.
Treatment of erectile dysfunction through the pharmacologic activity of tadalafil.
In some claims, limitations concerning dosage, administration frequency, or the clinical context.

The commercial value of the patent came from its relationship to Cialis labeling. A generic applicant seeking approval for erectile dysfunction could face a Paragraph IV issue if the Orange Book listed the patent against the relevant reference-listed drug and the applicant’s proposed labeling overlapped the patented method.

The patent’s legal strength was narrower than that of Lilly’s tadalafil composition patents. A composition patent generally covers the active ingredient regardless of indication. US7056712 depended on the asserted method and the accused product’s intended use, labeling, marketing, and prescribing environment.

How did US7056712 differ from the core tadalafil patents?

Lilly’s tadalafil estate contained multiple patent categories. They did not all provide the same level of protection.

Patent category	Representative subject matter	Strategic value
Composition of matter	Tadalafil and related chemical compounds	Strongest protection against direct tadalafil manufacture and sale
Pharmaceutical composition	Tadalafil-containing tablets and formulations	Protects product configuration and excipients
Method of treatment	Erectile dysfunction treatment	Depends on the claimed indication and use
Dosing regimen	Frequency, dose, or timing of administration	Can delay generic labeling or require carve-outs
Additional indications	Benign prostatic hyperplasia and related conditions	Supports post-Cialis lifecycle management
Manufacturing process	Synthesis, intermediates, or purification	May create process-specific barriers

The earlier tadalafil patents, including U.S. Patent Nos. 5,859,006 and 6,140,329, were more closely associated with the underlying active ingredient and early Cialis development. U.S. Patent No. 6,821,975 and later patents addressed additional uses, formulations, or dosing concepts. Patent number alone does not establish the commercial importance of a listing. Claim scope, Orange Book listing status, expiration, pediatric extensions, and the reference product’s labeling determine actual entry risk.

When did US7056712 expire?

US7056712 reached the end of its effective U.S. patent term in approximately 2021, subject to the patent-term-adjustment calculation and any applicable regulatory extension.

The expiration date should be distinguished from several other dates:

Date type	Significance
Priority date	Determines priority and contributes to the patent family
Filing date	Relevant to prosecution and term calculations
Grant date	Does not normally establish the expiration date for modern U.S. patents
Patent-term adjustment	Can extend the term for USPTO delay
Patent-term extension	Can extend certain pharmaceutical patents for FDA review
Orange Book expiration	The operative date used in FDA patent-listing analysis

The principal patent term for a patent filed after June 8, 1995, is generally 20 years from the earliest effective nonprovisional filing date, subject to adjustments under 35 U.S.C. §§ 154 and 156. The Orange Book remains the controlling commercial reference for listed patent information, not third-party patent databases alone (FDA, 2024).

What was the Orange Book status of US7056712?

US7056712 was part of the Cialis patent estate identified in FDA Orange Book records. Orange Book-listed patents can trigger a four-year stay of approval when an NDA holder timely sues an ANDA applicant after receiving a Paragraph IV notice.

The listing did not automatically block all tadalafil products. Its effect depended on:

Whether the generic application referenced Cialis or another tadalafil product.
Whether the patent was still listed when the ANDA was filed.
Whether the ANDA applicant made a Paragraph IV certification.
Whether Lilly filed suit within the statutory period.
Whether the generic label included the patented indication.
Whether the patent remained unexpired when FDA approval became effective.

Method-of-use patents can be addressed through a section viii statement or a label carve-out when the applicant excludes the patented indication and the FDA-approved labeling permits that approach. A carve-out does not eliminate all litigation risk if the applicant’s marketing, package materials, or actual conduct supports induced-infringement allegations.

Which companies challenged the Cialis patent estate?

Multiple generic-drug companies challenged or prepared to challenge the Cialis estate through ANDA filings and Paragraph IV certifications. Publicly reported challengers and market participants included Teva Pharmaceuticals, Watson Pharmaceuticals, Mylan, and other generic manufacturers.

The principal litigation pattern involved:

Filing an ANDA for tadalafil tablets.
Certifying that listed Cialis patents were invalid, unenforceable, or not infringed.
Sending Paragraph IV notices to Lilly.
Lilly filing patent-infringement litigation.
Settlement or court resolution establishing a permitted generic-launch date.

Teva reached an agreement with Lilly that allowed an authorized or licensed generic pathway before or around the broader expiration timetable. Generic tadalafil products entered the U.S. market in 2018, well before the expiration of every later Cialis-related patent, through settlement arrangements, authorized-generic supply, label strategies, or products unaffected by particular claims (FTC, 2018; FDA, 2018).

The existence of a generic launch did not necessarily mean every Cialis patent was invalid. Commercial entry can occur through a license, a settlement date, a non-infringing label, or an agreement covering only specified patents.

What patent litigation affected US7056712?

The litigation risk associated with US7056712 was part of broader Cialis ANDA litigation. Lilly’s cases generally asserted multiple patents together rather than relying on one method-of-use patent in isolation.

The main legal issues were:

Whether the asserted claims were valid over prior tadalafil clinical data and earlier PDE5-inhibitor disclosures.
Whether the claims were enabled across the full claimed dosage and treatment scope.
Whether the claims were obvious in view of sildenafil, tadalafil research, and clinical-development publications.
Whether generic tadalafil labeling induced infringement.
Whether a proposed label carve-out adequately removed the patented indication.
Whether the patent listing supported a statutory stay of FDA approval.

Method-of-use patents are often vulnerable to divided-infringement and induced-infringement arguments. Direct infringement requires performance of each claimed treatment step. Induced infringement requires evidence that the manufacturer knew of the patent and encouraged conduct that constituted infringement. FDA-approved labeling is important evidence, but courts also examine marketing, promotional statements, distribution materials, and foreseeable use.

How strong was the patent estate for tadalafil?

The overall tadalafil estate was stronger than US7056712 considered alone. Lilly combined early molecule protection with later patents directed to indications, dosing, formulations, and product lifecycle management.

Strengths

The original tadalafil patents created substantial early protection.
Cialis generated a large and commercially important product base.
Multiple patents increased litigation leverage.
Method-of-use patents could delay an unrestricted erectile-dysfunction label.
The Lilly-ICOS development history supported ownership and commercialization rights.

Weaknesses

Later patents had narrower claim scope.
Method-of-use claims depended on labeling and actual use.
Tadalafil is a small molecule with no biosimilar-style manufacturing barrier.
Generic applicants could challenge validity, pursue settlements, or use label carve-outs.
Expiration of the core patents reduced the value of later litigation.

Once the composition and principal formulation patents expired, the remaining estate could support only narrower forms of protection. It could not preserve full market exclusivity for tadalafil tablets indefinitely.

What licensing deals affected tadalafil commercialization?

Tadalafil was developed through the relationship between ICOS Corporation and Eli Lilly. Lilly and ICOS formed a development and commercialization partnership for tadalafil, and Lilly later acquired ICOS. That acquisition consolidated the commercial and patent position under Lilly ownership (Eli Lilly and Company, 2006).

The transaction mattered because it unified:

Cialis commercialization rights.
The tadalafil patent portfolio.
Regulatory ownership and product strategy.
Litigation control.
International licensing and distribution decisions.

Separate regional licensing and commercialization arrangements also affected tadalafil availability outside the United States. Patent rights, regulatory approvals, and settlement terms varied by jurisdiction.

Was there biosimilar risk for tadalafil?

No. Tadalafil is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway was the abbreviated new drug application, not the biosimilar pathway under the Public Health Service Act.

Generic risk depended on:

ANDA approval.
Bioequivalence.
Patent certifications.
Labeling strategy.
Manufacturing capacity.
State substitution laws.
Wholesale and pharmacy contracting.

There was no biosimilar interchangeability issue comparable to monoclonal antibodies or other biologic products.

What generic launch scenarios existed?

The principal generic-launch scenarios were:

Scenario	Commercial consequence
Paragraph IV success	Early unrestricted or substantially unrestricted launch
Patent settlement	Launch on an agreed date before later patent expiration
Authorized generic	Lilly-controlled or licensed supply with limited competition
Section viii carve-out	Approval for non-patented indications or uses
Post-expiration launch	Broad competition after the relevant patent term ends
At-risk launch	Generic entry before final resolution, exposing the applicant to damages or injunction risk

By 2018, the market had moved from an exclusivity dispute to a competition phase. The expiration of US7056712 removed its standalone method-of-use barrier, but product-level commercial outcomes continued to depend on other Cialis patents, FDA labeling, and contractual settlements.

How does US7056712 compare with Viagra patents?

US7056712 and the Viagra patent estate protected different products and patent positions.

Issue	Tadalafil and Cialis	Sildenafil and Viagra
Active ingredient	Tadalafil	Sildenafil
Originator	Eli Lilly and ICOS	Pfizer
Core market	Erectile dysfunction, later BPH	Erectile dysfunction, pulmonary arterial hypertension under Revatio
Patent strategy	Composition, use, dosing, formulation	Composition, use, formulation, pediatric and regulatory extensions
Generic pathway	Tadalafil ANDAs	Sildenafil ANDAs
Biosimilar relevance	None	None
Main litigation issue	Labeling, use claims, settlement timing	Composition and use patents, labeling and indication scope

Tadalafil gained a commercial duration advantage from once-daily dosing, longer half-life, and additional BPH use. That commercial differentiation did not automatically produce broader patent claims.

What manufacturing and geographic barriers remained?

The patent estate did not create a permanent manufacturing monopoly after expiration. Commercial barriers remained in:

Active pharmaceutical ingredient qualification.
Control of polymorphs and particle characteristics.
Impurity specifications.
Tablet compression and stability.
Bioequivalence testing.
FDA inspection readiness.
Global registration requirements.
Supply-chain scale and pricing.

Geographic protection depended on national patent rights. U.S. expiration did not terminate patents in Europe, Japan, Canada, or other jurisdictions. Each country required separate analysis of priority, prosecution, supplementary protection certificates, pediatric extensions, compulsory licensing rules, and local litigation.

Key Takeaways

US7056712 was a tadalafil method-of-treatment patent directed to erectile dysfunction.
It was weaker in isolation than the core tadalafil composition patents.
Its principal commercial value came from its inclusion in Lilly’s broader Cialis patent estate.
The patent reached the end of its U.S. term around 2021.
Tadalafil competition proceeded through Paragraph IV challenges, settlements, authorized-generic arrangements, and FDA-approved ANDA products.
Tadalafil has no biosimilar risk because it is a small-molecule drug.
Remaining commercial barriers are primarily manufacturing, regulatory, supply-chain, and pricing barriers rather than US7056712 itself.
Any current freedom-to-operate review must examine other U.S. and foreign tadalafil patents, Orange Book records, and settlement restrictions separately.

FAQs About U.S. Patent 7,056,712

Did US7056712 cover the tadalafil molecule itself?

No. It was principally a method-of-treatment patent. The core molecule was protected by separate tadalafil composition patents.

Could a generic company sell tadalafil before US7056712 expired?

Yes, depending on the product label, patent certifications, settlement terms, authorized-generic rights, and whether the proposed use fell within the asserted claims.

Did US7056712 cover tadalafil for benign prostatic hyperplasia?

The patent was associated with erectile-dysfunction treatment. BPH protection was addressed through separate tadalafil patents and regulatory labeling strategies.

Is US7056712 still enforceable against generic tadalafil?

The patent’s ordinary U.S. term has ended. It is not a current standalone exclusionary right.

Does tadalafil require a biosimilar application?

No. Tadalafil products are approved through the ANDA pathway as generic drugs, subject to bioequivalence and patent-certification requirements.

References

Eli Lilly and Company. (2006). Annual report 2006.
Food and Drug Administration. (2018). FDA approves first generic versions of Cialis.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
Federal Trade Commission. (2018). Authorized generic drugs: Short-run effects and long-run impact.
United States Patent and Trademark Office. (2006). U.S. Patent No. 7,056,712: Tadalafil for the treatment of erectile dysfunction.
21 U.S.C. § 355.
35 U.S.C. §§ 154, 156.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	28-Apr-06	7,056,712	2021-07-10
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	24-May-10	7,056,712	2021-07-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 7,056,712

Summary for Patent: 7,056,712